arrow
J

Jin-Yong Hwang

Gyeongsang National University
H指数:30
被引数:4,128

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcomes according to absolute value vs. percentage reduction in low-density lipoprotein cholesterol levels after acute myocardial infarction

急性心肌梗死后,根据低密度脂蛋白胆固醇水平的绝对值与百分比降幅的长期结局

2025-12-050
OAAI
Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug-Eluting Stent Implantation

根据临床风险分层在药物洗脱支架植入术后CYP2C19基因型的预后意义

2025-12-010
PRE
Renal function-dependent risk of early invasive strategy in patients with non-ST-segment elevation myocardial infarction: insight from KAMIR-NIH and KRAMI-RCC
2025-11-010
PRE
The Clinical Impact of Intravascular Imaging-Guided Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with High Thrombus Burden

高血栓负荷急性心肌梗死患者中血管内影像引导下经皮冠状动脉介入治疗的临床影响

2025-09-010
PRE
Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION–STEMI): a multicentre, non-inferiority, open-label, randomised trial

在ST段抬高型心肌梗死合并多支血管病变患者首次入院期间,即刻与分阶段完全血运重建的比较(OPTION–STEMI):一项多中心、非劣效性、开放标签、随机试验

2025-08-310
PRE
Potent P2Y12 inhibitors in patients with acute myocardial infarction and cardiogenic shock

急性心肌梗死合并 cardiogenic shock 患者中的强效 P2Y12 抑制剂

2025-02-060
OA
Intravascular imaging-guided percutaneous coronary intervention in patients with acute myocardial infarction and cardiogenic shock

血管内成像引导下经皮冠状动脉介入治疗急性心肌梗死合并心源性休克

2024-12-010
PRE
Clinical Impact of Self-Recognition of Recurrent Acute Myocardial Infarction: From KRMI-RCC
2024-08-160
OAAI
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Non-ST-Elevation Myocardial Infarction
2024-07-250
OA
Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial
2024-07-010
OAAI
The Efficacy and Tolerability of Irbesartan/Amlodipine Combination Therapy in Patients With Essential Hypertension Whose Blood Pressure Were not Controlled by Irbesartan Monotherapy
2024-06-010
PRE